Skip to main content

BeiGene Ltd. (BGNE)

NASDAQ: BGNE · IEX Real-Time Price · USD
358.43 2.97 (0.84%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap33.43B
Revenue (ttm)947.04M
Net Income (ttm)-1.31B
Shares Out93.33M
EPS (ttm)-14.49
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume126,935
Open358.55
Previous Close355.46
Day's Range351.05 - 359.21
52-Week Range219.20 - 426.56
Beta0.79
AnalystsBuy
Price Target424.26 (+18.4%)
Est. Earnings DateNov 4, 2021

About BGNE

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China and the United States. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblast...

IndustryBiotechnology
IPO DateFeb 3, 2016
CEOJohn Oyler
Employees6,400
Stock ExchangeNASDAQ
Ticker SymbolBGNE
Full Company Profile

Financial Performance

In 2020, BeiGene's revenue was $308.87 million, a decrease of -27.87% compared to the previous year's $428.21 million. Losses were -$1.60 billion, 68.3% more than in 2019.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for BeiGene stock is "Buy." The 12-month stock price forecast is 424.26, which is an increase of 18.37% from the latest price.

Price Target
$424.26
(18.37% upside)
Analyst Consensus: Buy

News

BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma

SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma

5 days ago - Business Wire

BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia

5 days ago - Business Wire

BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with ...

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines...

1 week ago - Business Wire

2 Outperforming Biotech Stocks to Examine on Covid-19 Vaccine Updates

With recent updates from Pfizer Inc. ( PFE , Financial) and BioNTech SE ( BNTX , Financial) regarding the effectiveness of their Covid-19 vaccine among children ages 5 to 11 and Johnson & Johnson's ( JN...

Other symbols:BNTXJNJPFEREGN
3 weeks ago - GuruFocus

BeiGene Stock Rises 46% In A Month But Will The Rally Continue?

The stock price of BeiGene, a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a rise of 46% over the last twenty-one trading days, while it...

3 weeks ago - Forbes

BeiGene Announces Inclusion in FTSE Russell Indices

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announced inclusion in several FTSE Russell indices.

3 weeks ago - Business Wire

Why BeiGene Shares Are Rising

Beigene Ltd (NASDAQ: BGNE) shares are trading higher by 3.8% at $400 after the company announced it received a positive CHMP opinion for BRUKINSA for the treatment of adults with Waldenström's macroglob...

4 weeks ago - Benzinga

Why BeiGene's Shares Jumped on Friday

The Chinese pharmaceutical company is racking up approvals for its lead oncology drug, Brukinsa.

4 weeks ago - The Motley Fool

BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström's Ma...

BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the Eur...

4 weeks ago - Business Wire

BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma

The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.

4 weeks ago - Zacks Investment Research

3 Top Chinese Stocks to Watch in September

There are plenty of risks, but the rewards could be great.

Other symbols:BABATME
1 month ago - The Motley Fool

BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma

The FDA has granted accelerated approval to BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-ba...

1 month ago - Benzinga

U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

1 month ago - Business Wire

BeiGene's (BGNE) BLA for Tislelizumab in ESCC Accepted by FDA

The FDA accepts for review BeiGene's (BGNE) BLA for tislelizumab to treat patients with locally advanced/metastatic esophageal squamous cell carcinoma after prior systemic therapy.

1 month ago - Zacks Investment Research

BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell C...

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable med...

1 month ago - Business Wire

BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

1 month ago - Business Wire

Why BeiGene Stock Is Soaring This Week

The company won another FDA approval for blood cancer drug Brukinsa.

1 month ago - The Motley Fool

BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion

The FDA approves BeiGene's (BGNE) Brukinsa for the treatment of adult patients with Waldenstrom's macroglobulinemia. This marks the second approval for the drug in the United States.

1 month ago - Zacks Investment Research

BeiGene's Brukinsa Scores FDA Approval For Rare Blood Cancer Indication

The FDA has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenström's macroglobulinemia (WM). Brukinsa WM approval is the second therapy approved...

1 month ago - Benzinga

U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström's Macroglobulinemia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE--U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström's Macroglobulinemia

1 month ago - Business Wire

Tonight! Novartis, Roche, BeiGene, Others Discuss Global Fight Against Cancer In Covid Era

Against that backdrop, Forbes China will hold the second “Forbes China Healthcare Summit” at 8pm ET tonight (8am on August 28 in China).

Other symbols:NVS
1 month ago - Forbes

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyng...

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

1 month ago - Business Wire

BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for BRUKINSA® (Zanubrutinib) in Wal...

BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, a...

1 month ago - Business Wire

BeiGene's Pediatric Tumor Drug Scores Conditional Approval In China

The China National Medical Products Administration (NMPA) granted conditional approval for BeiGene Ltd (NASDAQ: BGNE) - EUSA Pharma's (UK) Qarziba (dinutuximab beta) in high-risk neuroblastoma patients....

1 month ago - Benzinga

BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients With High-Risk Neuro...

CAMBRIDGE, Mass. & BEIJING & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Admini...

1 month ago - Business Wire